Within the European pharmacovigilance system, the Qualified Person for Pharmacovigilance (QPPV) holds formal responsibility for the functioning of a company’s pharmacovigilance system.
This role is mandatory for Marketing Authorization Holders (MAHs) in the European Union (EU) and the European Economic Area (EEA), namely companies that place medicinal products on the market.
A QPPV must possess specific expertise and experience in drug safety and pharmacovigilance.
In addition, European legislation requires the QPPV to reside within the EEA and remain continuously available. This ensures that regulatory authorities can contact the QPPV at any time and that critical safety issues, such as emerging safety signals or situations requiring urgent action, can be addressed promptly.
Within this framework, the QPPV serves as the primary point of contact between the company and regulatory authorities, including the European Medicines Agency (EMA) and national competent authorities, ensuring the coordinated and timely management of safety information.
What does a QPPV do?
The role of the QPPV extends far beyond performing individual operational activities. Instead, it focuses on the overall oversight of the company’s pharmacovigilance system.
More specifically, the QPPV is responsible for ensuring that the system operates effectively and in compliance with regulatory requirements. This includes overseeing the collection, assessment, and reporting of adverse event information within the required timelines, while ensuring that pharmacovigilance processes are managed with appropriate levels of quality and control.
Another important responsibility involves the management and maintenance of the Pharmacovigilance System Master File (PSMF), the document that comprehensively describes the company’s pharmacovigilance system and must remain continuously updated and available for inspection by regulatory authorities.
The QPPV is also involved in safety signal management and in the evaluation of the benefit-risk profile of medicinal products. Through these activities, potential safety concerns can be identified, assessed, and addressed in a timely and appropriate manner.
One of the most significant aspects of the role is ultimate responsibility for the pharmacovigilance system. Although supported by dedicated teams and operational structures, the QPPV remains accountable for the overall effectiveness and compliance of the company’s pharmacovigilance activities.
The role of the QPPV within the organization
Within the organization, the QPPV occupies a cross-functional position that provides visibility across the entire pharmacovigilance system and throughout the lifecycle of medicinal products.
The role operates at the interface of several departments, including Medical Affairs, Regulatory Affairs, Quality Assurance, and Clinical Operations. This positioning enables the integration of information from different areas, promoting consistency and alignment across safety-related activities and processes.
Rather than performing day-to-day operational tasks directly, the QPPV primarily acts as a coordinator and facilitator. This helps ensure that critical safety information flows efficiently throughout the organization and that all relevant stakeholders share a consistent approach to safety management.
As a result, the QPPV serves as a key link between internal business functions and the external regulatory environment, supporting the integration of company processes, regulatory requirements, and safety information management.
Conclusions
The Qualified Person for Pharmacovigilance (QPPV) is a key figure within the European pharmacovigilance system, with responsibilities that extend well beyond the operational management of safety activities.
By maintaining a comprehensive overview of the pharmacovigilance system and acting as a bridge between company departments and regulatory authorities, the QPPV helps ensure that safety processes remain structured, compliant, and effective in addressing regulatory requirements and emerging safety concerns.
Understanding the role of the QPPV also provides insight into how pharmacovigilance operates within pharmaceutical companies: a complex system built on integrated processes, expertise, and responsibilities, all aimed at achieving a common objective—protecting patient safety.
References
- European Medicines Agency (EMA) – Good Pharmacovigilance Practices (GVP), Module I: Pharmacovigilance systems and their quality systems
- European Medicines Agency (EMA) – Good Pharmacovigilance Practices (GVP), Module II: Pharmacovigilance System Master File (PSMF)
- European Medicines Agency (EMA) – Role of the Qualified Person for Pharmacovigilance (QPPV)
- European Commission – Directive 2001/83/EC (as amended) – Pharmacovigilance requirements
- European Medicines Agency (EMA) – Guideline on good pharmacovigilance practices (GVP) – Introduction and general principles